[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"paediatrics\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:paediatrics":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,52,79],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":34,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100644540","phase-3-tranexamic-acid-to-reduce-blood-loss-after-varus-derotation-osteotomy-100644540",false,"NCT07672158","Tranexamic Acid to Reduce Blood Loss After Varus Derotation Osteotomy","Postoperative Continuous Intravenous Tranexamic Acid Infusion to Reduce Blood Loss in Non-Ambulatory Children With Cerebral Palsy Following Bilateral Bony Hip Reconstructive Surgery: A Phase III Parallel-Group Randomised Placebo-Controlled Trial","TABLO","Inclusion Criteria:\n\n* Children (aged 4 to 16 years)\n* Diagnosis of cerebral palsy (CP). CP is an umbrella term under which many specific diagnoses are captured, and the clinical team at the study institution operates a comprehensive referral network to ensure patients with any relevant diagnoses are included.\n* Gross Motor Function Classification System (GMFCS) levels IV and V, with substantial hip displacement (\\>40% migration percentage per Australian Hip Surveillance Guidelines (Wynter M, Gibson N, Kentish M, Love S, Thomason P, Willoughby K, et al. Australian hip surveillance guidelines for children with cerebral palsy 2014. Australian Academy of Cerebral Palsy and Developmental Medicine. 2014.)), who are on the waitlist for bilateral proximal femoral varus derotational osteotomy (VDRO) +\u002F- unilateral or bilateral pelvic osteotomy.\n\nExclusion Criteria:\n\n* Haematological disorder (defined as an active genetic or acquired bleeding disorder)\n* Known hypersensitivity to tranexamic acid (TXA)\n* Children with promyelocytic leukaemia being treated with oral tretinoin will be excluded from the trial because combination with TXA has resulted in fatal thrombotic complications\n* Known coagulation defect\n* Known renal disorder (moderate to severe as per study institution guidelines)","ALL","4 Years","16 Years",{"count":21,"type":22},52,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","TABLO (Tranexamic Acid to reduce Blood Loss after varus derotation Osteotomy) is a clinical trial of postoperative tranexamic acid vs placebo in non-ambulatory children with cerebral palsy (CP) undergoing reconstructive hip surgery.\n\nImproving surgical outcomes is a high priority in this patient population given the high risk of bleeding and the diminished capacity for these children to withstand substantial blood loss. Preliminary data from the study institution indicates that approximately one third of these patients receive transfusion of blood products in the postoperative period. There is growing evidence that hidden blood loss occurring in the postoperative period is substantial and can potentially be attenuated with the administration of Tranexamic Acid (TXA). However, trials on postoperative TXA have been carried out exclusively in adult surgical populations.",[28,29,30,31,32,33],"Cerebral Palsy","Hip Surgery Corrective","Tranexamic Acid Use","Blood Loss, Surgical","Paediatrics","Orthopedics",[28,35,36,37,38],"Hip surgery","Tranexamic Acid","Blood Loss","Orthopaedics","NOT_YET_RECRUITING","2026-06-23",{"date":42,"type":43},"2026-06-26","ACTUAL",{"date":45,"type":22},"2026-07",{"date":47,"type":22},"2029-04",{"name":49,"class":50},"Murdoch Childrens Research Institute","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":17,"minAge":59,"maxAge":19,"enrollmentInfo":60,"targetDuration":4,"studyType":23,"phases":62,"briefSummary":64,"conditions":65,"keywords":66,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":51},"100609138","acceptability-gastrointestinal-tolerance-compliance-and-palatability-study-100609138","NCT07210658","Acceptability, Gastrointestinal Tolerance, Compliance and Palatability Study.","Acceptability (Including Gastrointestinal Tolerance, Compliance and Palatability) of a Paediatric Oral Nutritional Supplement Containing Food Blends.","Inclusion Criteria:\n\n* Patients from 1-15 years requiring 1 or more oral nutritional supplement to replace current oral nutritional supplement as part of their dietary management for disease related malnutrition.\n* Patients well-established and stable on current nutritional support regimen.\n* Willingly given, written, informed consent from patient\u002Fcaregiver.\n\nExclusion Criteria:\n\n* Unsafe swallow\n* Inability to comply with the study protocol, in the opinion of the investigator.\n* Under 1 years of age\n* Patients on total parenteral nutrition\n* Known food allergies, including any allergies to the ingredients\n* Patients with Chronic Kidney Disease (CKD) stage 3b (G3b), stage 4 (G4), stage 5 (G5) or hepatic impairment.\n* Participation in another interventional study within 2 weeks of this study.\n* Patients with known or suspected ileus or mechanical bowel obstruction","1 Year",{"count":61,"type":22},25,[63],"NA","Acceptability, compliance and palatability study.",[32],[67],"Acceptability","RECRUITING","2026-01-08",{"date":71,"type":43},"2026-01-09",{"date":73,"type":43},"2025-04-14",{"date":75,"type":22},"2026-05-15",{"name":77,"class":78},"Société des Produits Nestlé (SPN)","INDUSTRY",{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":17,"minAge":86,"maxAge":87,"enrollmentInfo":88,"targetDuration":4,"studyType":23,"phases":90,"briefSummary":92,"conditions":93,"keywords":100,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":51},"100594803","phase-4-comparison-of-the-effectiveness-of-paracetamol-with-ibuprofen-or-paracetamol-with-metamizole-in-treating-pain-in-acute-pancreatitis-in-children-100594803","NCT07024199","Comparison of the Effectiveness of Paracetamol With Ibuprofen or Paracetamol With Metamizole in Treating Pain in Acute Pancreatitis in Children","Comparison of the Effectiveness of Paracetamol With Ibuprofen or Paracetamol With Metamizole in Treating Pain in Acute Pancreatitis in Children: a Randomized Trial","Inclusion Criteria:\n\n* diagnosis of AP according to the INSPPIRE mentioned above criteria,\n* age from 3 to 18 years of age,\n* abdominal pain on admission assessed on the Numerical Rating Scale (NRS) or FLACC \\>= 4 points,\n* no analgesic treatment before enrolment in the study OR the last dose of analgesic drug (paracetamol, ibuprofen, metamizole) taken ≥ 6 hours before enrolment for examination,\n* consent of legal guardians and the child (in the case of patients ≥16 years of age) to participate in the study.\n\nExclusion Criteria - patients:\n\n* who took the last dose of painkiller (paracetamol, ibuprofen, metamizole) \\\u003C 6 hours before entering the study,\n* allergic to acetylsalicylic acid, other NSAIDs, paracetamol, metamizole,\n* with inflammatory bowel disease,\n* with gastrointestinal bleeding and other active bleeding,\n* with gastric and\u002For duodenal ulcer disease,\n* chronically taking paracetamol, NSAIDs, metamizole,\n* with liver failure,\n* with heart failure according to the NYHA II-IV scale,\n* with acute and chronic renal failure,\n* with cancer,\n* whose legal guardians did not consent to participate in the study,\n* who did not consent to participate in the study (applies to patients \\> 16 years of age).","3 Years","18 Years",{"count":89,"type":22},78,[91],"PHASE4","The aim of the study is to assess the effectiveness and tolerance of pain treatment in AP in children using intravenous paracetamol in combination with ibuprofen or paracetamol in combination with metamizole. The study is prospective, interventional, and randomized.",[94,95,96,97,98,99,32],"Pancreatitis, Acute","Pain, Acute","Pancreatic Disease","Pancreatic Diseases","Gastroenterology","Pancreatitis",[101,102,103,104],"acute pancreatitis","acute pain","painkillers","pancreatitis","2025-08-18",{"date":107,"type":43},"2025-08-24",{"date":109,"type":22},"2025-09",{"date":111,"type":22},"2027-06-01",{"name":113,"class":50},"Medical University of Warsaw"]